167 filings
Page 4 of 9
8-K
fdrdqxuby
6 Mar 17
Regulation FD Disclosure
12:00am
8-K
cf4bwru0 xdfbh4t7
28 Feb 17
Cempra Provides Corporate Update and Reports Fourth
12:00am
8-K
6e8euu6qh83zf 5m31d
24 Feb 17
Cempra’s Fusidic Acid Achieves Primary Endpoint In Phase 3 Study of Absssi
12:00am
8-K
nlkx 8dvamjudak38gwq
9 Jan 17
Regulation FD Disclosure
12:00am
8-K
iiczr0 zyrf
29 Dec 16
CEMPRA RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR SOLITHROMYCIN NDAs
12:00am
8-K
uri3 c93jad6x
12 Dec 16
Cempra Appoints DR. David Zaccardelli As Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
12:00am
8-K
jq77docw
5 Dec 16
Begins Phase 3 Studies In Japan with Cempra’s Solithromycin
12:00am
8-K
cqy1i5cdxt 3m3x7yzsb
15 Nov 16
Regulation FD Disclosure
12:00am
8-K
s5okjf
10 Nov 16
Other Events
12:00am
8-K
pxk61bw
7 Nov 16
Fda Advisory Committee Votes That Efficacy Results of
12:00am
8-K
oly5606
1 Nov 16
Cempra Receives $10 Million Milestone Payment from
12:00am
8-K
1oie3hru 8n81
27 Oct 16
Cempra Reports Third Quarter 2016 Financial Results and Provides
12:00am
8-K
c9b4bckf
30 Sep 16
Interim Results from Phase 2 Study
12:00am
8-K
5phpxe
8 Sep 16
Other Events
12:00am
8-K
jrabq ayzw1dhruamdjb
30 Aug 16
Cempra to Present Solithromycin at Fda Antimicrobial
12:00am
8-K
ruw95 lby
23 Aug 16
Cempra Announces European Medicines Agency Validates Maa for Solithromycin for Treatment of Cabp
12:00am
8-K
8yn5mamk7r0qxzpcjwn
11 Aug 16
Cempra Appoints DR. David Zaccardelli to
12:00am
8-K
t5081wqn
1 Aug 16
Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
brpoz3n7 odof5u70dd
6 Jul 16
Cempra Announces FDA Acceptance of Solithera™ New Drug
12:00am
8-K
nz23f7m altkinl
28 Jun 16
Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
12:00am